MUSK and myasthenia gravis: The data in this study reveals heterogeneity in the MuSK MG population regarding the therapeutic potential of MuSK agonist ARGX-119 and suggests that the effect of ARGX-119 may depend on the nature of the individual MuSK autoimmune response.